Merck completes acquisition of investigational B-Cell depletion therapy, CN201, from Curon Biopharmaceutical
Acquiring Company
Merck
Acquired Company
Curon Biopharmaceutical
Rahway
ShanghaiManufacturingBiotechnologyHealthcareHealth CareBiotechnologyHealth CareTherapeuticsDescription
Merck has announced the completion of the acquisition of CN201 from Curon Biopharmaceutical, a next-generation CD3xCD19 bispecific antibody with potential applications in B-cell malignancies and autoimmune diseases. This acquisition broadens and fortifies Merck’s pipeline for the treatment of B-cell associated diseases.
Quick answer
Merck is acquiring Curon Biopharmaceutical, announced October 1, 2024. Merck is based in Rahway, New Jersey, United States.
- How much did Merck pay for Curon Biopharmaceutical?
- The deal value was not disclosed.
- What does Merck do?
- For over 130 years, Merck, known as MSD outside of the United States and Canada, has been inventing for life, bringing forward medicines and vaccines for many of the world’s most challenging diseases in pursuit of our..
- Where are Merck and Curon Biopharmaceutical based?
- Merck is based in Rahway, New Jersey, United States. Curon Biopharmaceutical is based in Shanghai, Shanghai, China.
- Who are the decision-makers at Merck?
- Fundz holds 3 contacts at Merck. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Other recent acquisitions in Healthcare and Therapeutics
Deals where the buyer or target shares a sector with this one, within 45 days, from Fundz verified event records.
- Boston Scientific completes acquisition of Axonics, Inc. to expand into sacral neuromodulation (November 15, 2024)
- AbbVie announces acquisition of Aliada Therapeutics, focusing on Alzheimer's disease and neuroscience pipeline (October 28, 2024)
- Merck completes acquisition of Modifi Biosciences, Inc. to advance DNA modification enabled cancer therapeutics (October 23, 2024)
- BD completes acquisition of Edwards Lifesciences' Critical Care product group to expand its smart connected care solutions portfolio (September 3, 2024)
- Flashpoint Therapeutics announces $50M Partnership with KAIMRC and Clinical Pipeline Expansion (November 14, 2024)
- Celltrion acquires iQone Healthcare Switzerland to strengthen European expansion (November 14, 2024)
Who to call at Merck, and when
When Merck changes hands, the new owners review vendors, systems and leadership. That is when the door opens.
- An alert the day Merck raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Merck, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Merck. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Merck makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Frequently asked
Who acquired Curon Biopharmaceutical?
Curon Biopharmaceutical was acquired by Merck, based in Rahway. The deal was reported on October 1, 2024. Merck is publicly traded (MRK) and operates in Manufacturing.
When did Merck acquire Curon Biopharmaceutical?
Merck's acquisition of Curon Biopharmaceutical was reported on October 1, 2024. Merck has announced the completion of the acquisition of CN201 from Curon Biopharmaceutical, a next-generation CD3xCD19 bispecific antibody with potential applications in B-cell malignancies and autoimmune diseases. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does Curon Biopharmaceutical do?
Curon Biopharmaceutical is a Shanghai-based biopharma company. Curon Biopharma currently holds multiple promising novel cancer immuno-therapeutic agents in its pipeline, and is committed to bring next generation cancer immunotherapies to patients. It is privately held, operating in Biotechnology, and is based in Shanghai.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.